MDM2 overexpression generates a skin phenotype in both wild type and p53 null mice
- PMID: 10050879
- DOI: 10.1038/sj.onc.1202448
MDM2 overexpression generates a skin phenotype in both wild type and p53 null mice
Abstract
The MDM2 proto-oncogene is overexpressed in human tumours and regulates the activities of the tumour suppressors p53 and pRB. We created mice that overexpress MDM2 under the control of the CMV promoter. These mice did not display an increased tumour incidence, but rather a specific skin phenotype, characterized by desquamation and hyperkeratosis. Transgenic MDM2 was found to be overexpressed in the epidermis, a tissue that normally expresses high levels of MDM2. The phenotype appeared during the first week after birth and then lessened with age, closely following the level of expression of the transgene. MDM2 overexpression was associated with an increase in proliferation in the basal layer, thickening of the epidermis, altered expression of the differentiation markers cytokeratin CK14, CK10 and CK1, and a decrease in the size and the number of granules that contain products of differentiation. Transgenic mice on a p53 null background displayed similar although not identical changes, showing that the effects of MDM2 are to a certain degree p53 independent. The skin is a major site of MDM2 expression in mice, raising the possibility that MDM2 overexpression perturbs the normal pattern of MDM2 expression and inhibits differentiation of the epidermis.
Similar articles
-
MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis.EMBO J. 2000 Oct 2;19(19):5135-47. doi: 10.1093/emboj/19.19.5135. EMBO J. 2000. PMID: 11013216 Free PMC article.
-
Decreased survival of C/EBP beta-deficient keratinocytes is due to aberrant regulation of p53 levels and function.Oncogene. 2007 Jan 18;26(3):360-7. doi: 10.1038/sj.onc.1209797. Epub 2006 Jul 10. Oncogene. 2007. PMID: 16832342
-
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.Nature. 1995 Nov 9;378(6553):206-8. doi: 10.1038/378206a0. Nature. 1995. PMID: 7477327
-
Mdm2: keeping p53 under control.Oncogene. 1997 Aug 28;15(9):1001-10. doi: 10.1038/sj.onc.1201432. Oncogene. 1997. PMID: 9285554 Review.
-
p53 and Mdm2: not all cells are equal.J Pathol. 2007 Dec;213(4):357-9. doi: 10.1002/path.2275. J Pathol. 2007. PMID: 17973240 Review.
Cited by
-
A mitosis block links active cell cycle with human epidermal differentiation and results in endoreplication.PLoS One. 2010 Dec 20;5(12):e15701. doi: 10.1371/journal.pone.0015701. PLoS One. 2010. PMID: 21187932 Free PMC article.
-
The mysterious human epidermal cell cycle, or an oncogene-induced differentiation checkpoint.Cell Cycle. 2012 Dec 15;11(24):4507-16. doi: 10.4161/cc.22529. Epub 2012 Oct 31. Cell Cycle. 2012. PMID: 23114621 Free PMC article. Review.
-
Natural product MDM2 inhibitors: anticancer activity and mechanisms of action.Curr Med Chem. 2012;19(33):5705-25. doi: 10.2174/092986712803988910. Curr Med Chem. 2012. PMID: 22830335 Free PMC article. Review.
-
MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis.EMBO J. 2000 Oct 2;19(19):5135-47. doi: 10.1093/emboj/19.19.5135. EMBO J. 2000. PMID: 11013216 Free PMC article.
-
A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.Cancer Causes Control. 2009 Mar;20(2):171-9. doi: 10.1007/s10552-008-9231-9. Epub 2008 Sep 24. Cancer Causes Control. 2009. PMID: 18814047 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous